As researchers continue to delve into the potential of psilocybin, understanding its risks is crucial for ensuring that the ...

Imagine a world where doctors could give their patients a list of every clinical trial they are eligible to join.

Regeneron’s clinical trials are at the core of this mission. Regeneron is grateful to all clinical trial participants — ...

Esperion (ESPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from ...

with manageable hyperkalemia risks through protocolized monitoring and dose adjustments, maintaining clinical benefits even ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

Study links hallucinogen use to higher schizophrenia risk, highlighting the need for caution and informed decisions on ...

Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patientsBoth artificial ...

A range of concerns have been raised, including: Reliance on surrogate endpoints could put patients at risk if approved drugs ...

Real-world data on GLP-1R agonists’ safety in heart failure and CKD patients was investigated using the TriNetX Research ...

Nothing about pregnancy diminishes an individual’s decision-making capacity or obviates their right to make decisions related ...

Modern medical innovations continue to transform treatment approaches for chronic conditions, and Ozempic stands at the ...